Condition (MeSH)
Ectodermal Dysplasia 1, Anhidrotic
ClinicalTrials.gov lists 21 trials for Ectodermal Dysplasia 1, Anhidrotic or a narrower condition beneath it. Edimer Pharmaceuticals has the most among industry and government lead sponsors, with 13.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 21 trials are tagged with Ectodermal Dysplasia 1, Anhidrotic itself; the rest are tagged with a narrower condition beneath it.
When did Ectodermal Dysplasia 1, Anhidrotic trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2014 | 2 |
| 2013 | 2 |
| 2012 | 3 |
| 2011 | 6 |
| 2010 | 2 |
| 2009 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 21 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ectodermal Dysplasia 1, Anhidrotic trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Not applicable | 1 |
| Observational | 17 |
How many Ectodermal Dysplasia 1, Anhidrotic trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 18 |
| Withdrawn | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ectodermal Dysplasia 1, Anhidrotic trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Edimer Pharmaceuticals | 13 |
| Dermelix Biotherapeutics, LLC. | 1 |
| Pierre Fabre Medicament | 1 |
Which drugs are being tested for Ectodermal Dysplasia 1, Anhidrotic? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EDI200 | 4 |
Which publications cover Ectodermal Dysplasia 1, Anhidrotic? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. | Genes | 2023 | Yes |
| A Causal Treatment for X-Linked Hypohidrotic Ectodermal Dysplasia: Long-Term Results of Short-Term Perinatal Ectodysplasin A1 Replacement. | International journal of molecular sciences | 2023 | Yes |
| Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. | The New England journal of medicine | 2018 | Yes |
| Systematic evaluation of exertional hyperthermia in children and adolescents with hypohidrotic ectodermal dysplasia: an observational study. | Pediatric research | 2011 | Yes |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| X-linked hypohidrotic ectodermal dysplasia | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| X-linked hypohidrotic ectodermal dysplasia | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| X-linked hypohidrotic ectodermal dysplasia | Point prevalence | 1-5 / 10 000 | Denmark | Not stated | Exact |
| X-linked hypohidrotic ectodermal dysplasia | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| X-linked hypohidrotic ectodermal dysplasia | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| X-linked hypohidrotic ectodermal dysplasia | 181 | Exact | Orphadata Science knowledge files, Product 1 |
| X-linked hypohidrotic ectodermal dysplasia | 181 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.